You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Jemperli logo

Product menu

Endometrial Cancer image
Durable, Biomarker-Directed Treatment Options Are Needed1

For treatment approaches in advanced or recurrent endometrial cancer.

Globally, Incidence of Endometrial Cancer Is Rising, and Mortality Is Also Increasing2-5

carboplatin

For Over 10 Years
carboplatin + paclitaxel has been the standard of care for initial systemic treatment6

dMMR/MSI-H Are Important Biomarkers in Endometrial Cancer Due to Prognostic and Predictive Factors7,8

  • Tumours with dMMR/MSI-H are more likely to respond to anti–PD-1 therapies like JEMPERLI8,9*

*Increased mutations promote antitumour immune cell reaction and increased tumour-infiltrating lymphocytes.8,9

endometrial tumours

~25%-30%

of endometrial tumours are dMMR/MSI-H; the highest rate across cancer types1,10-13

Anti–PD-1=anti-programmed death receptor 1; dMMR=mismatch repair deficient; MSI-H=microsatellite instability-high.

Test All Your Patients With Primary Advanced or Recurrent Endometrial Cancer, for MMR/MSI Status, as Recommended by ESMO Guidelines8

Testing may help determine appropriate patients for JEMPERLI + platinum-containing chemotherapy14

dMMR endometrial cancer tumours can be associated with7,15:

  • a higher rate of recurrence7
  • a higher rate of distant recurrences7
  • a mutation that increases the risk of other cancers (Lynch syndrome)15

Modalities to Test for dMMR/MSI-H15

Testing for dMMR

IHC
dMMR: Loss of ≥1 MMR protein

Testing for MSI-H

PCR/NGS
MSI-H: DNA repeats are unstable

ESMO=European Society for Medical Oncology; IHC=immunohistochemistry; MMR=mismatch repair; MSI=microsatellite instability; NGS=next-generation sequencing; PCR=polymerase chain reaction.

RUBY Efficacy Data

Discover RUBY Data

GARNET Efficacy Data

Discover GARNET Data

JEMPERLI Is Indicated14

  • in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
  • as monotherapy for the treatment of adult patients with dMMR/ MSI‑H recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.

Jemperli Safety Information14

Contraindications: 
Hypersensitivity to the active substance or to any of the excipients

Adverse reactions:

Dostarlimab monotherapy:
Very common: Anaemia, Hypothyroidism, Diarrhoea, nausea, vomiting, Rash, pruritus, Arthralgia, Pyrexia and Transaminases increased

Common: Hyperthyroidism, adrenal insufficiency, Pneumonitis, Colitis , pancreatitis, gastritis, Hepatitis, Myalgia, Chills and Infusion-related reaction

Dostarlimab in combination therapy:
Very common: Hypothyroidism, Rash, dry skin, Pyrexia, Alanine aminotransferase increased and aspartate aminotransferase increased

Common: Hyperthyroidism, adrenal insufficiency, Pneumonitis and Colitis

▼ This medicine is subjected to additional monitoring. This will allow quick identification of new safety information. You may help by reporting any side effects you may get.

References

  1. Makker V, et al. Gynecol Oncol Res Pract. 2017;4(19):1-12.
  2. Sung H, et al. CA Cancer J Clin. 2021;71(3):209-249.
  3. Lortet-Tieulent J, et al. J Natl Cancer Inst. 2018;110(4):354-361.
  4. Ferlay J, et al. Int J Cancer. 2015;136(5):E359-E386.
  5. Ferlay J, et al. Int J Cancer. 2019;144(8):1941-1953.
  6. Miller D, et al. Gynecol Oncol. 2012;125(3):771.
  7. Backes FJ, et al. Cancer. 2019;125(3):398-405.
  8. Oaknin A, et al. Ann Oncol. 2022;33(9):860-877.
  9. Le DT, et al. N Engl J Med. 2015;372(26):2509-2520.
  10. Le DT, et al. Science. 2017;357(6349):409-413.
  11. The Cancer Genome Atlas. Nature. 2013;497(7447):67-73.
  12. Lorenzi M, et al. J Oncol. 2020;1-17.
  13. Bonneville R, et al. JCO Precis Oncol. 2017;2017:1-15.
  14. Jemperli Local PI
  15. Walk EE, et al. Arch Pathol Lab Med. 2020;144(6):706-724.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Drug Safety Center
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357690
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

 دائرة التيقظ و المعلومات الدوائية
مركز سلامة الدواء
وزارة الصحة, سلطنة عمان
هاتف: 0096822357687 / 0096822357690
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد االكتروني
www.moh.gov.om : الموقع االكتروني

Trademarks are owned by or licensed to the GSK group of companies 

February 2025 | PM-AE-DST-WCNT-250001